Novel, Selective Histone Methyltransferase SET7 Inhibitor

Novel PRC2 Inhibitor, Targeting EZH2-EED Interaction

Novel potent and selective DCN1-UBC12 inhibitor for anticardiac fibrotic effects, specifically targetinbg DCN1 at molecular and cellular levels, effectively reversing angiotensin (Ang) II-induced cardiac fibroblast activation

Novel potent CDK2 inhibitor with selectivities above 10-fold over CDK1/4/6/7/9/12 above 10-fold, displaying anti-proliferative activity against A2058 melanoma and MV4-11 leukemia cell lines and low toxicity on human normal cell lines, inhibiting CDK2-medi

Highly potent agonist for group II mGlu receptors

Novel inhibitor of lysine methyltransferase G9a

Activator of IK and SK channels

Novel potent EZH2 inhibitor

Novel potent EZH2 inhibitor

Novel potent CBP bromodomain inhibitor with a TR-FRET IC50 value of 19.5 ± 1.1 nM and over 400-fold of selectivity against BRD4 bromodomains

Novel potent BPTF-BRD inhibitor, showing selectivities 100-fold higher than those of other BRD targets

Novel potent BPTF-BRD inhibitor, showing selectivities 100-fold higher than those of other BRD targets, significantly inhibiting leukemia cell proliferation

Inhibitor of N-methyl transferases (NMT), preventing the formation of Parkinson's syndrome neurotoxins via methylation of non-methylated pre-neurotoxins.

Novel inhibitor of menin-MLL interaction

Novel inhibitor of menin-MLL interaction

Novel inhibitor of menin-MLL interaction

Novel inhibitor of WDR5-MLL1 interaction

Novel selective non-nucleoside inhibitor of DNA methyltransferase 1 (DNMT1)

Potent HCV NS5A inhibitor

p38 MAPK inhibitor, supressing p38 phosphorylation and LPS-induced TNF-α production in macrophages

Novel protein cross-linking agent

Novel antileishmanial agent, against both intracellular Leishmania donovani and intracellular Leishmania amazonensis and displaying dose-dependent reduction of liver parasitemia

Novel ERG/DNA binding inhibitor, targeting the DNA-binding activity of the human ERG transcription factor

Novel tyrosine kinase inhibitor for drug resistant T315I mutant BCR-ABL

Biological Active Reagents

Novel selective ionotropic glutamate receptor 5 (iGluR5) antagonist

Novel glucagon analog for diabetic hypoglycemia therapy

Novel PROTAC targeting drug-resistant BCR-ABL

Proteolysis targeting chimeras (PROTAC), acting as a degrader of oncogenic BCR-ABL

Proteolysis targeting chimeras (PROTAC), acting as a degrader of oncogenic BCR-ABL